Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Look cLoseLy at who we are 31 if you save one life, you save the world. take a close look at our world. 3 THE sanofi-aventis Group sanofi-aventis around the world •A leader in prescription medicines, vaccines, consumer healthcare products, generic medicines and animal health •105,000 employees in 110 countries •Strong presence in both established and emerging* markets •Over 18,900 research staff at more than 25 R&D centres on three continents •2009 net sales of 29.3 billion euros •2009 R&D investment of 4.6 billion euros A diversified global healthcare leader, focused on patients’ needs Sanofi-aventis is the world’s fourth largest pharmaceutical company, and holds the leading position in Europe and several emerging markets. With nearly 100,000 employees in more than 100 countries, the company offers a broad range of medicines in a number of key therapeutic areas: diabetes, oncology, cardiovascular diseases, thrombosis, central nervous system disorders and internal medicine. The Group’s vaccines division, sanofi-pasteur, is the world leader in human vaccine production and sales, offering the broadest range of products protecting against 20 infectious diseases. The company is also the world’s fifth largest supplier of consumer healthcare products and a major supplier of generic medicines and animal health products. Global net sales in 2009 amounted to 29.3 billion euros. 4 * Emerging markets include Brazil, Russia, India, China and Mexico 5 Three strategies to meet our goals Our Group has launched an ambitious transformation program to achieve the diversification and sustainable growth that will enable us to meet the needs of patients around the world in the years to come. We’re focusing on three strategies to bring about this transformation. 3. Adapting our structures to future challenges 1. Boosting innovation in R&D We have created two integrated global business divisions in Diabetes and Oncology. This allows us to concentrate our forces and improve our responsiveness in areas where there is an urgent healthcare need and where, owing to our experience and expertise, we have much to offer. At the global level, we’re streamlining our product pipeline to focus on projects with the greatest potential for success. We’re also forming partnerships and signing collaborative research agreements with specialized external organizations. By joining forces with the best, we’re confident we can accelerate the development of novel compounds and vaccines to ensure patients benefit faster from leading-edge medical discoveries. Meeting the needs of patients and healthcare systems around the world requires us to be more flexible and responsive than ever before. We’re tackling this challenge in a couple of ways. To enhance our ability to meet healthcare needs that vary from region to region, our Group is decentralizing many of its structures and shifting decision-making power to local teams closest to our customers. 2. Seizing external growth opportunities Our Group is acquiring businesses and forming new partnerships with companies in Europe, the Americas and Asia, in fields that offer opportunities for sustainable growth. This strategy is reinforcing our number one position in vaccines and positioning us among the world leaders in consumer healthcare, generic medicines and animal health. 6 7 THE sanofi-aventis Group in canada Sanofi-aventis Canada – Pharmaceuticals For nearly one hundred years, sanofi-aventis and its predecessor companies have pioneered innovative products and techniques to improve the health and lives of Canadians. Bringing value, health and hope to Canadians through innovative healthcare solutions Our Group has two major areas of activity in Canada. We operate in pharmaceuticals under the name of sanofi-aventis Canada, based in Laval, Quebec, and in vaccines under the name of sanofi-pasteur Limited, based in Toronto, Ontario. Together we employ more than 2,000 people across the country. Backed by decades of service to Canadian healthcare professionals and patients, we’ve found that genuine inspiration comes from looking at healthcare challenges from our customers’ perspective. Diversification strategy in Canada Our global diversification strategy is changing the face of our operations in Canada, as the Group acquires international companies with a presence in this country. Examples include the animal health company Merial, which became a wholly owned subsidiary of the Group in 2009, and the consumer healthcare company Chattem, which was acquired in 2010. 8 We have reorganized our field-based teams to meet the needs that differ from region to region, and to respond effectively to new structures and roles within our healthcare systems: health authorities, primary care networks, prescribing pharmacists and nurse practitioners, to name a few. We are partnering with these customers to ensure they derive the best possible value from our diverse product portfolio. Our joint initiatives include programs to promote the appropriate use of medicines and complementary services to improve standards of care and help people better manage their health. Our manufacturing plant in Laval maintains the highest level of safety, quality and customer satisfaction. This nimble and efficient operation produces a wide range of tablets, liquids, capsules, ointments and creams. Export volumes in particular are on the rise, as we secure a steady stream of international manufacturing mandates from our parent company. More than half the medications produced in Laval are destined for other countries, mainly the U.S. and Australia. 9 Pharmaceuticals at a glance •Corporate office and industrial site in Laval, Quebec, founded in 1968 by Octo Laboratories •Draws on the strengths of numerous legacy organizations in Canada, starting with Rhône-Poulenc in the 1920s and continuing with innovative companies such as Nordic, Marion Merrell Dow, Hoechst Marion Roussel, SanofiSynthelabo and Aventis •Employs 900 people across the country, including 540 at the Laval site •Offers products in diabetes, oncology, cardiovascular disease, thrombosis, internal medicine and dermatology (under the brand name Dermik) 10 take a close look at our world 11 Sanofi-Pasteur – Vaccines A public healthcare pioneer Founded in 1914 as Connaught Laboratories, our sanofi-pasteur site has a long and illustrious history as a pioneer in public health. Scientists working at this site developed techniques for the world’s first large-scale insulin production and, over the decades, vaccines and serums against diphtheria, smallpox, tetanus and meningitis. They developed techniques for large-scale production of polio vaccine, helping bring an end to the epidemics in North America in the 1950s. More recent milestones include the research and development of a fivecomponent pertussis vaccine used to protect children and adults around the world from whooping cough. take a close look at our world Our Toronto site continues to evolve. In 2010 we will open a $100 million R&D facility to support its role as a global sanofi-pasteur centre of excellence in biopharmaceutical development. 12 13 A powerful presence for protection around the world Internationally, sanofi-pasteur holds a leading position in most countries. In the U.S., which accounts for 40% of the global vaccine market, sanofi-pasteur is one of the top two vaccine companies. In Canada, sanofi-pasteur is the country’s largest vaccine manufacturer, protecVaccines at a glance ting Canadians against •Corporate office, R&D and industrial site infectious diseases with in Toronto, Ontario an extensive product •Canada’s largest producer of vaccines portfolio for close to a •Manufactures more than 50 million doses century. In Europe, our annually vaccines are commercia•Distributes vaccines to more than lized in 19 countries by 90 countries around the world sanofi-pasteur. In emer•Employs 1,100 people in Canada, nearly ging countries, which all at the Toronto site account for 80% of the world population, sanofi-pasteur has established a leading position, notably in Latin America and increasingly in Asia, where we have been expanding our presence. We are also very active in donor’s markets such as UNICEF and Pan-American Health Organization. 14 take a close look at our world 15 Top investor in innovative biopharmaceutical R&D In 2009 the sanofi-aventis Group* was one of the top R&D spenders in Canada’s innovative biopharmaceutical industry, with joint investments of C$211.5 million. take a close look at our world Our Canadian pharmaceuticals business has acquired particular expertise in the area of clinical studies, which evaluate the safety and efficacy of medications. We currently operate the second largest clinical research unit of the entire sanofi-aventis Group. The Canadian healthcare professionals and researchers taking part in our international clinical trials are helping to define therapies and healthcare practices that can have an impact around the world. In 2009 our vaccines site in Toronto was named a global centre of excellence for biopharmaceutical development for the global sanofi-pasteur organization. It will specialize in analytical and biopharmaceutical R&D. 16 * sanofi-aventis (pharmaceuticals) and sanofi-pasteur (vaccines). 17 Social responsibility at sanofi-aventis Social responsibility is a priority for us and takes many forms. Our most unique initiative, which truly sets sanofi-aventis apart within the industry, is our Group’s Access to Medicines division. This business group produces high-quality medicines and vaccines for underprivileged populations based on a “no profit, no loss” pricing policy. Production facilities are located in the developing regions they serve, providing economic stimulus and employment. Access to Medicines programs focus on malaria, tuberculosis, tropical diseases, epilepsy, mental health and vaccines, and include education and information programs. 18 take a close look at our world 19 In Canada, we support: United Way/Centraide. Employees raised more than $310,000 in 2009. Health Partners International of Canada. Works through partnerships to increase access to medicine and improve health in the developing world. March of Dimes. Aims to enhance the independence and community participation of children and adults with physical disabilities through a wide range of programs and services. Sanofi-aventis Biotech Challenge. Annual Canada-wide competition, founded in 1994 by sanofi-pasteur, that encourages students to pursue careers in biotechnology. Advanced Coronary Treatment (ACT) Foundation. Promotes training of high school students in cardiopulmonary resuscitation and heart health. PROCURE. Supports and conducts activities aimed at preventing and curing prostate cancer. take a close look at our world The Heart and Stroke Foundation. Provides information about the heart, stroke, atrial fibrillation and healthy living. The Colorectal Cancer Association of Canada. Supports patients and advocates for population-based screening and timely access to effective treatments. The Canadian Diabetes Association and Diabetes Québec. Support people affected by diabetes by providing information, diabetes research, education, service and advocacy. 20 21 Sound environmental practices Concern for the environment runs high at both our major Canadian sites, where employees have put in place many exemplary practices. take a close look at our world 22 In Laval, we recycle 86% of our residual materials and have earned the highest level of certification from the Quebec government’s “ICI on recycle” program. Used office supplies are donated to local schools; our cafeteria sends food waste for composting and uses no disposable dishes or cutlery. To reduce the carbon footprint at our Toronto site, we opened a cogeneration plant in 2007 and apply “Green Building” concepts in new and renovated facilities. Storm water is used for landscape irrigation. We have switched to reusable or recyclable packaging for vaccines, and donate to charity the money we receive from the resale of used polyethylene suits, which are recuperated by other industries. 23 sanofi-aventis products sanofi-aventis products our therapeutic approach to fundamental health issues Sanofi-aventis is a leader in developing medicines for treatments for Canadians in several therapeutic areas: cardiovascular disease, thrombosis, oncology, metabolic disorders, the central nervous system and internal medicine. Cardiovascular products PLAVIX® take a close look at our world INDICATION MI, Stroke or Established Peripheral Arterial Disease PLAVIX® (clopidogrel) is indicated for the secondary prevention of atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with atherosclerosis documented by stroke, MI, or established peripheral arterial disease. Acute Coronary Syndrome PLAVIX®, in combination with acetylsalicylic acid (ASA), is indicated for the early and long-term secondary prevention of atherothrombotic events (myocardial infarction, ischemic stroke, cardiovascular death and/or refractory ischemia) in patients with acute coronary syndromes - without ST-segment elevation (i.e., unstable angina or non-Q-wave myocardial infarction). These benefits of PLAVIX® have been shown only when these patients were concomitantly treated with ASA in addition to other standard therapies. 24 25 sanofi-aventis products LOVENOX® For patients with ST-segment elevation acute myocardial infarction, PLAVIX® has been shown to reduce the rate of an endpoint of allcause mortality and the rate of a combined endpoint of death, reinfarction, or stroke. • The prophylaxis of thromboembolic disorders (deep vein thrombosis) in patients undergoing: LOVENOX® (enoxaparin) is indicated for: AVAPRO® INDICATIONS - high risk abdominal, gynecological, or urological surgeries AVAPRO® (irbesartan) is indicated for the treatment of essential hypertension. - colorectal surgery AVALIDE® INDICATIONS AVALIDE® (irbesartan/hydrochlorothiazide) is indicated for the treatment of essential hypertension in patients for whom combination therapy is appropriate. AVALIDE® is also indicated as initial therapy in patients with severe essential hypertension (sitting DBP ≥110 mm Hg) for whom the benefit of a prompt blood pressure reduction exceeds the risk of initiating combination therapy in these patients. AVALIDE® is not indicated as initial therapy in patients with mild to moderate essential hypertension. 26 INDICATION - orthopaedic surgery of the hip or knee. In addition, LOVENOX® is indicated in hospital or after hospital discharge for long-term prevention of venous thromboembolic diseases following hip replacement surgery AVAPRO® is also indicated for the treatment of hypertensive patients with Type 2 diabetes mellitus and renal disease to reduce the rate of progression of nephropathy as measured by the reduction of microalbuminuria, and the occurrence of doubling of serum creatinine. AVAPRO® may be used alone or concomitantly with thiazide diuretics. The safety and efficacy of concurrent use with angiotensin converting enzyme inhibitors has not been established. sanofi-aventis products These benefits were also seen in patients who were managed medically and those who were managed with percutaneous coronary intervention (with or without stent) or CABG (coronary artery bypass graft). • The prophylaxis of deep vein thrombosis (DVT) in medical patients who are at moderate risk of DVT and who are bedridden due to moderate to severe acute cardiac insufficiency (NYHA Class III or IV heart failure), acute respiratory failure revealing or complicating chronic respiratory insufficiency not requiring ventilatory support and acute respiratory infections (excluding septic shock), who require short-term prophylaxis of deep vein thrombosis • The treatment of deep vein thrombosis, with or without pulmonary embolism • The treatment of unstable angina or non-Q-wave myocardial infarction, concurrently with ASA • Treatment of acute ST-segment Elevation Myocardial Infarction (STEMI), including patients to be managed medically or with subsequent Percutaneous Coronary Intervention MULTAQ® INDICATIONS MULTAQ® (dronedarone) is indicated for the treatment of patients with a history of, or current, atrial fibrillation to reduce the risk of cardiovascular hospitalization due to atrial fibrillation. 27 sanofi-aventis products Altace® (ramipril) Angiotensin Converting Enzyme Inhibitor Altace® HCT (ramipril, hydrochlorothiazide) Angiotensin Converting Enzyme Inhibitor—Diuretic Nitrolingual® Pumpspray* (nitroglycerin) * Trademark of G. Pohl-Boskamp GmbH & Co. Commercialized in Canada by sanofi-aventis. Antianginal Renedil® (felodipine) Antihypertensive APIDRA® sanofi-aventis products Other cardiovascular products INDICATIONS APIDRA® [insulin glulisine (rDNA origin)] is a recombinant human insulin analogue indicated for the treatment of adult patients with Type 1 or Type 2 diabetes mellitus where treatment with insulin is required. APIDRA® has a more rapid onset of action and a shorter duration of action than regular human insulin. APIDRA® should normally be used in regimens that include a longer-acting insulin or basal insulin analogue to maintain adequate glucose control. APIDRA® can be used with oral hypoglycemic agents. Rythmodan®/Rythmodan® LA (disopyramide) Antiarrhythmic Sectral® (acebutolol hydrochloride) Antihypertensive—Antianginal Zaroxolyn® (metolazone) Diuretic—Antihypertensive Other diabetes products Diabeta® (glyburide) Oral Hypoglycemic Glucophage®* (metformin hydrochloride) Lasix®/Lasix® Oral Solution (furosemide) Diuretic * Trademark of Merck Santé s.a.s. Commercialized in Canada by sanofi-aventis. Lasix® Special (furosemide) Diuretic Amaryl® (glimepiride) Oral Hypoglycemic Agent (Sulfonylurea) Diabetes products Oral Antihyperglycemic Agent ClikStar® and SoloStar® State-of-the-art reusable injection pens available for basal insulin LANTUS® (grey pen) and for rapid acting APIDRA® (blue pen). LANTUS® INDICATION LANTUS® [insulin glargine injection (rDNA origin)] is a novel recombinant human insulin analog indicated for once-daily subcutaneous administration in the treatment of patients over 17 years of age with Type 1 or Type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. LANTUS® is also indicated in the treatment of pediatric patients with Type 1 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. 28 29 sanofi-aventis products ACTONEL ® INDICATIONS ACTONEL (risedronate sodium hemi-pentahydrate) is indicated for: ® • The treatment and prevention of osteoporosis in postmenopausal women • The treatment of osteoporosis in men, to improve bone mineral density • The treatment and prevention of glucocorticoid-induced osteoporosis in men and women • Paget’s disease of bone Other bone and joint products Actonel®* (risedronate sodium)/Actonel® Plus Calcium (risedronate sodium, calcium carbonate) * Trademark of P&G Pharmaceuticals Inc. Commercialized in Canada by sanofi-aventis and P&G Pharmaceuticals. Bone Metabolism – Mineral Regulator Calcimar (calcitonin-salmon) Calcium Regulator ® Arava® (leflunomide) Antirheumatic Agent Myochrysine (sodium aurothiomalate) Antirheumatic Agent ® Oncology sanofi-aventis products Bones/joints TAXOTERE® INDICATIONS NOC/c TAXOTERE® (docetaxel for injection) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. The effectiveness of TAXOTERE® in combination with doxorubicin and cyclophosphamide is based on improved disease-free survival and overall survival in comparison to the combination of fluorouracil, doxorubicin and cyclophosphamide at a median follow up of 55 months. However, long-term data are not yet available.TAXOTERE® is indicated for the treatment of patients with locally advanced or metastatic breast cancer. TAXOTERE®, in combination with doxorubicin as first-line therapy, should be reserved for patients with potentially life-threatening disease (such as visceral or lung metastatic disease). TAXOTERE® in combination with Xeloda® (capecitabine) is indicated for the treatment of patients with advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. Non-Small Cell Lung Cancer: TAXOTERE® is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer in monotherapy or in combination with platinum derivatives. Ovarian Cancer: TAXOTERE® is indicated for the treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy. Prostate Cancer: TAXOTERE® in combination with prednisone or prednisolone is indicated for the treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer. Squamous Cell Carcinoma of the Head and Neck: TAXOTERE® is indicated as monotherapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after failure of a previous chemotherapy regimen. 30 31 sanofi-aventis products ELOXATIN® INDICATIONS ELOXATIN® (oxaliplatin for injection) in combination with infusional 5-fluorouracil/leucovorin (5-FU/LV) is indicated for: •A djuvant treatment of patients with stage III (Dukes’ C) colon cancer after complete resection of primary tumor. The indication is based on a demonstrated improvement in disease-free survival. Survival data at 6 years show a numerical improvement in overall survival • Treatment of patients with metastatic colorectal cancer ELIGARD® Demerol® (meperidine hydrocholoride) Analgesic Talwin® (pentazocine hydrochloride) Narcotic Analgesic Dermatology Dermatop® Ointment/Dermatop® Emollient Cream (prednicarbate) Topical Corticosteroid Drisdol® (ergocalciferol) Antirachitic Agent BenzaClin™ (clindamycin, benzoyl peroxide) Acne Vulgaris Therapy INDICATIONS Benzamycin® (erythromycin, benzoyl peroxide) Acne Therapy ELIGARD® (leuprolide acetate) is indicated for the palliative treatment of advanced prostate cancer (stage D2). Loprox® Cream/Loprox® Lotion (ciclopirox olamine) Topical Antifungal ELIGARD® should be administered by a healthcare professional. Noritate® (metronidazole) Antirosacea Agent Other Oncology Products Anandron® (nilutamide) Nonsteroidal Antiandrogen Anzemet® (dolasetron mesylate) Antiemetic Suprefact® (buserelin acetate)/Suprefact® Depot 2 months/Suprefact® Depot 3 months (buserelin acetate implant) Luteinizing Hormone-Releasing Hormone (LHRH) Analog Tamofen®* (tamoxifen citrate) * Trademark of Schering Oy. Commercialized in Canada by sanofi-aventis. Antineoplastic Fasturtec® (rasburicase) Uricolytic Agent 32 Pain relief products sanofi-aventis products TAXOTERE® should be administered under the supervision of a physician experienced in the use of antineoplastic agents. Penlac® (ciclopirox) Topical Antifungal pHisoHex®* (hexachlorophene) * Trademark of The Mentholatum Company of Canada, Ltd. Commercialized in Canada by sanofi-aventis. Antibacterial—Skin Cleanser Sulfacet®-R (sulfacetamide sodium, sulfur) Acne Therapy Topicort®/Topicort® Mild/Topicort® Gel/Topicort® Ointment (desoximetasone) Topical Corticosteroid Vitamin A Acid Acne Therapy Sculptra™ (poly-L-lactic acid) 33 sanofi-aventis products Allegra® 12 hour/Allegra® 24 hour (fexofenadine hydrochloride) Histamine H1-Receptor Antagonist Allegra®–D (fexofenadine hydrochloride, pseudoephedrine hydrochloride) Histamine H1-Receptor Antagonist—Sympathomimetic Amine Eltor 120 (pseudoephedrine hydrochloride) Nasal Decongestant ® Nalcrom® (sodium cromoglycate) Antiallergic Nasacort® AQ (triamcinolone acetonide) Corticosteroid Sofracort® (framycetin sulphate, gramicedin, dexamethasone) Antibiotic—Corticosteroid Suprax®* (cefixime) * Trademark of Astellas Pharma Inc. Commercialized in Canada by sanofi-aventis. Antibiotic Plaquenil® (hydroxychloroquine sulfate) Anti-inflammatory—Antimalarial Primaquine® (primaquine phosphate) Antimalarial Psychiatry Novahistex DH (hydrocodone bitartrate, phenylephrine hydrochloride) Antitussive—Decongestant Imovane® (zopiclone) Hypnotic—Sedative Novahistine® DH (hydrocodone bitartrate, phenylephrine hydrochloride) Antitussive—Decongestant Mersyndol® with Codeine (acetaminophen, codeine phosphate, doxylamine succinate) Acetaminophen—codeine phosphate—doxylamine Tussionex® Suspension and Tablets (hydrocodone resin complex, phenyltoloxamine resin complex) Antitussive—Antihistamine Nozinan® (methotrimeprazine) Neuroleptic ® Infectious Diseases Claforan® (cefotaxime sodium) β-lactam Antibiotic Flagyl (metronidazole) Antibacterial—Antiprotozoal ® Flagystatin (metronidazole, nystatin) Trichomonacide—Moniliacide ® Ketek® (telithromycin) Antibacterial Rifadin® (rifampin) Antibiotic 34 Rifater® (rifampin, isoniazid, pyrazinamide) Antituberculous Antibiotic sanofi-aventis products Respiratory Piportil L4® (pipotiazine palmitate) Antipsychotic Gynecology Clomid® (clomiphene citrate) Selective Estrogen Receptor Modulator Cyclomen® (danazol) Ovulatory Agent Gastroenterology Gastrolyte® (electrolytes and dextrose oral powder) Antidiarrheal 35 sanofi-aventis products Kayexalate (sodium polystyrene sulfonate) Cation-Exchange Resin ® Resonium® Calcium (calcium polystyrene sulfonate) Ion-Exchange Resin Trental® (pentoxifylline) Vasoactive Agent CNS we are the world’s largest company devoted entirely to human vaccines sanofi-pasteur VACCINES Haematology Sanofi-pasteur has a broad range of vaccines, protecting against 20 infectious diseases. Rilutek® (riluzole) Antiglutamate Urology Xatral® (alfuzosin hydrochloride) Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)— Adjunctive Therapy in Acute Urinary Retention (AUR) Vaccines Disease(s) Product Meningococcal Disease MENACTRATM (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diptheria Toxoid Conjugate Vaccine) Anti-inflammatory Pediapred® (prednisolone sodium phosphate) Glucocorticoid—Anti-inflammatory Cholera, Travellers' Diarrhea DUKORAL® (Oral, inactivated travellers’ diarrhea and cholera vaccine) Diphtheria, Tetanus, Whooping PEDIACEL® Cough, Poliomyelitis and (Component Pertussis Vaccine Haemophilus influenzae type b and Diphtheria and Tetanus Toxoids Adsorbed Combined with Inactivated Poliomyelitis Vaccine and Haemophilus b Conjugate Vaccine) Diphtheria, Haemophilus influenzae type b, Pertussis, Poliomyelitis, Tetanus 36 PENTACEL® (Haemophilus b conjugate vaccine reconstituted with component pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine) 37 sanofi-pasteur VACCINES Product Diphtheria, Pertussis, Poliomyelitis, Tetanus QUADRACEL Diphtheria, Pertussis, Tetanus ® (Component pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine) Diphtheria, Tetanus (Tetanus and diphtheria toxoids adsorbed and inactivated poliomyelitis vaccine - for 7 years and older) Td Adsorbed Haemophilus influenzae type b Act-HIB® (Hib) (Haemophilus b conjugate vaccine, tetanus protein - conjugate) Hepatitis A JE-VAX® (Japanese encephalitis virus vaccine inactivated) Meningococcal Disease MENOMUNE® A/C/Y/W-135 (Meningococcal polysaccharide vaccine, serogroups A,C,Y and W-135 combined) Pneumococcal Infections Pneumo 23® (23-valent pneumococcal polysaccharide vaccine) Poliomyelitis IMOVAX® Polio (Inactivated poliomyelitis vaccine) Tuberculosis BCG Vaccine Typhoid Fever Typhim Vi® (Salmonella typhi Vi capsular polysaccharide vaccine) Typhoid Fever ViVAXIM® (Combined Purified Vi Polysaccharide Typhoid and Inactivated Hepatitis A Vaccine) Avaxim® (Inactivated hepatitis A vaccine) Hepatitis A Japanese Encephalitis Td Polio Adsorbed (Tetanus and diphtheria toxoids adsorbed - for 7 years and older) Hepatitis A Product ADACEL® (Tetanus and diphtheria toxoids adsorbed combined with component pertussis vaccine) Diphtheria, Poliomyelitis, Tetanus Disease(s) Yellow Fever YF-VAX® Avaxim® - Pediatric (Yellow Fever vaccine) (Inactivated hepatitis A vaccine) (Product may be ordered by designated Yellow Fever centers only) ViVAXIM® sanofi-pasteur VACCINES Disease(s) (Combined Purified Vi Polysaccharide Typhoid and Inactivated Hepatitis A Vaccine) Influenza Vaxigrip® (Inactivated influenza vaccine trivalent, types A and B - split virion) 38 39 sanofi-pasteur VACCINES Emergency Products Disease(s) Product Rabies Imovax® Rabies Vaccine (Rabies vaccine inactivated (DCO)) Rabies IMOGAM® Rabies Pasteurized (Rabies immune globulin, pasteurized (human)) Diagnostic Tests Disease(s) Product Tuberculin Skin Test TUBERSOL® (Tuberculin Purified Protein Derivative - Mantoux) OncoloGy Products Disease(s) Product Bladder Cancer ImmuCyst® take a close look at our world (Bacillus Calmette-Guérin (BCG), substrain Connaught) Please refer to product monographs for important information regarding contraindications, warnings, precautions, adverse reactions, dosing and patient selection. 40 41 A customer-focused approach… Improving healthcare relies as much on service as it does on science The best possible medical care requires not just a constant evolution of knowledge, but making that knowledge accessible to all concerned. Our goal of improving the health of all Canadians is built on an interdisciplinary approach with our customers… patient, physician, pharmacist, nurse. The objectives of each are intricately linked to the accomplishments of the others. Improving health outcomes is dependent on enhancing the knowledge and efficiency of stakeholders, be they patient or healthcare professional. At sanofi-aventis, this involves not only creating programs and services originating from within our company, but by fostering, nurturing and realizing ideas that may originate from you and your colleagues. 42 Collaboration and integration for optimal healthcare Canada’s Primary Care Networks (PCN) are beneficiaries Look closely at who we are of a two-pronged approach to advancing their knowledge-base. The first is focused on solidifying the patient-physician relationship with adherence programs designed to: • Ensure fulfillment of first prescriptions • Increase patient compliance and persistence • Increase patient empowerment and motivation The second approach is to improve PCN efficiency with training and CE programs designed to improve organization, technology and costeffectiveness. Patient adherence is as important to physicians working outside PCNs as those working within, and sanofi-aventis is committed to providing all physicians access to programs available to PCNs. As an integral member of the healthcare nexus, nurses are essential in ensuring and improving quality throughout the continuum of patient care. As well as compliance and adherence programs designed for nurses and their patients, sanofi-aventis provides training, education and workshops to meet their needs and to enhance nurse/patient interaction. 2150 St. Elzéar Blvd. West, Laval, Québec H7L 4A8 General inquiries: 514-331-9220, 1-800-363-6364 • Customer service: 1-800-265-7927 • Media inquiries: 1-877-904-2667 www.sanofi-aventis.ca www.sanofipasteur.ca 50092471 Collaboration and integration for optimal healthcare Canada’s Primary Care Networks (PCN) are beneficiaries Look closely at who we are of a two-pronged approach to advancing their knowledge-base. The first is focused on solidifying the patient-physician relationship with adherence programs designed to: • Ensure fulfillment of first prescriptions • Increase patient compliance and persistence • Increase patient empowerment and motivation The second approach is to improve PCN efficiency with training and CE programs designed to improve organization, technology and costeffectiveness. Patient adherence is as important to physicians working outside PCNs as those working within, and sanofi-aventis is committed to providing all physicians access to programs available to PCNs. As an integral member of the healthcare nexus, nurses are essential in ensuring and improving quality throughout the continuum of patient care. As well as compliance and adherence programs designed for nurses and their patients, sanofi-aventis provides training, education and workshops to meet their needs and to enhance nurse/patient interaction. 2150 St. Elzéar Blvd. West, Laval, Québec H7L 4A8 General inquiries: 514-331-9220, 1-800-363-6364 • Customer service: 1-800-265-7927 • Media inquiries: 1-877-904-2667 www.sanofi-aventis.ca www.sanofipasteur.ca 50092471